Article
The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.
The pharmacogenomics journal - 1 Jun 2016
Fabris M, Quartuccio L, Fabro C, Sacco S, Lombardi S, Ramonda R, Biasi D, Punzi D, Adami S, Olivieri I, Curcio F, De Vita S
Abstract excerpt
The genetic predisposition to a long-term efficacy of anti-tumor necrosis factor (TNF)α treatment in seronegative spondyloarthritis (SpA) was investigated by analysing the possible correlation between several single nucleotide gene polymorphisms and the retention rate of anti-TNFα therapies. We compared patients needing to switch the first anti-TNFα (Sw, No. 64) within at least 12 months of follow-up with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.